Steven D. Rubin
Sits on 6 boards. Overboarded · 6 public boards Last updated September 28, 2026
Time on boards
- Boards served
- 6
- Current seats
- 6
- Board service
- 18 years
- Director since
- 2023
18 years of board service in total across 6 boards, counting each seat separately. Longest: Eloxx Pharmaceuticals Inc., 3 years.
Shareholder support
Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
Cocrystal Pharma Inc. July 14, 202690.9%
-
Niagen Bioscience Inc. June 24, 202662.9%
-
OPKO Health Inc. June 18, 202688.3%
-
Red Violet Inc. June 3, 202644.9%
-
Cocrystal Pharma Inc. June 25, 202588.0%
-
Niagen Bioscience Inc. June 24, 202577.9%
-
Red Violet Inc. June 10, 202569.8%
-
OPKO Health Inc. April 23, 202595.8%
-
Cocrystal Pharma Inc. June 25, 202486.9%
-
Niagen Bioscience Inc. June 20, 202479.6%
-
Red Violet Inc. May 30, 202476.2%
-
OPKO Health Inc. March 28, 202492.9%
-
Eloxx Pharmaceuticals Inc. June 22, 202398.6%
-
OPKO Health Inc. June 22, 202382.3%
-
Niagen Bioscience Inc. June 15, 202381.2%
-
Red Violet Inc. May 31, 202384.6%
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 7, 2026 | Entera Bio Ltd. | Grant or award | +19,117 | — | — |
| Jul 24, 2026 | OPKO Health Inc. | Shares withheld for tax | −53,266 | $1.22 | $64,985 |
| Jun 4, 2026 | Red Violet Inc. | Grant or award | +2,179 | — | — |
| Feb 12, 2026 | Entera Bio Ltd. | Open-market purchase | +5,000 | $1.49 | $7,450 |
| Feb 9, 2026 | Entera Bio Ltd. | Open-market purchase | +10,000 | $1.20 | $12,000 |
| Jan 24, 2026 | Eloxx Pharmaceuticals Inc. | Option exercise | +1,875 | — | — |
| Dec 19, 2025 | Red Violet Inc. | Grant or award | +4,450 | — | — |
| Mar 19, 2025 | Red Violet Inc. | Open-market sale | −10,000 | $38.93 | $389,300 |
| Jan 24, 2025 | Eloxx Pharmaceuticals Inc. | Option exercise | +3,750 | — | — |
| Nov 4, 2024 | Red Violet Inc. | Grant or award | +8,000 | — | — |
| Oct 16, 2024 | Eloxx Pharmaceuticals Inc. | Grant or award | +12,000 | — | — |
| Oct 9, 2024 | Cocrystal Pharma Inc. | Grant or award | +18,957 | — | — |
| Jul 24, 2024 | OPKO Health Inc. | Grant or award | +437,500 | — | — |
| Jan 5, 2024 | OPKO Health Inc. | Open-market purchase | +10,000 | $0.87 | $8,700 |
| Nov 30, 2023 | Red Violet Inc. | Grant or award | +10,800 | — | — |
Questions about Steven D. Rubin
What boards is Steven D. Rubin on?
Steven D. Rubin sits on the boards of Cocrystal Pharma Inc., Eloxx Pharmaceuticals Inc., Entera Bio Ltd., Niagen Bioscience Inc., OPKO Health Inc. and Red Violet Inc.
How long has Steven D. Rubin served on boards?
Our records show at least 18 years of board service across 6 boards, the earliest from 2023.
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.